Targeted therapy of brain metastases: latest evidence and clinical implications
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy of brain metastases: latest evidence and clinical implications
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 9, Issue 12, Pages 781-796
Publisher
SAGE Publications
Online
2017-11-15
DOI
10.1177/1758834017736252
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
- (2017) Jonathan W. Riess et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
- (2016) E. Larkins et al. CLINICAL CANCER RESEARCH
- Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature
- (2016) Megan E. Gooch et al. Clinical Genitourinary Cancer
- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
- (2016) Shirish M. Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2016) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- (2016) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
- (2016) Mudit Chowdhary et al. OncoTargets and Therapy
- Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients
- (2015) M. Hecht et al. ANNALS OF ONCOLOGY
- LBA4 * EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
- (2015) D. Kerstein et al. ANNALS OF ONCOLOGY
- Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
- (2015) Gayathri Nagaraj et al. BREAST CANCER RESEARCH AND TREATMENT
- Activity of T-DM1 in Her2-positive breast cancer brain metastases
- (2015) Rupert Bartsch et al. CLINICAL & EXPERIMENTAL METASTASIS
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- (2015) S. Khozin et al. CLINICAL CANCER RESEARCH
- 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement
- (2015) A. Varga et al. EUROPEAN JOURNAL OF CANCER
- 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
- (2015) M.J. Ahn et al. EUROPEAN JOURNAL OF CANCER
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- (2015) Qingbei Zeng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment
- (2015) David Ly et al. JOURNAL OF NEUROSURGERY
- Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
- (2015) Petra Hoffknecht et al. Journal of Thoracic Oncology
- Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- (2015) Javier Cortés et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
- (2015) J. J. Harding et al. ONCOLOGIST
- Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
- (2015) Geoffrey T. Gibney et al. Cancer Medicine
- 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
- (2015) Hiroaki Kurihara et al. EJNMMI Research
- On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases
- (2014) C. Gaudy-Marqueste et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
- (2014) I. E. Krop et al. ANNALS OF ONCOLOGY
- Metastatic breast cancer subtypes and central nervous system metastases
- (2014) C. Aversa et al. BREAST
- Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
- (2014) L. Peuvrel et al. JOURNAL OF NEURO-ONCOLOGY
- LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases
- (2014) Kamran A. Ahmed et al. JOURNAL OF NEURO-ONCOLOGY
- Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
- (2014) Siow Ming Lee et al. JNCI-Journal of the National Cancer Institute
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases
- (2014) Marcin R. Dzienis et al. MELANOMA RESEARCH
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases
- (2013) Christine Chevreau et al. Clinical Genitourinary Cancer
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
- (2013) Reinhard Dummer et al. EUROPEAN JOURNAL OF CANCER
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
- (2013) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma
- (2013) Christopher J. Anker et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged Survival of a Patient With Papillary Renal Cell Carcinoma and Brain Metastases Using Pazopanib
- (2013) Corbin Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
- (2013) James W. Welsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib and radiation therapy in melanoma brain metastases
- (2013) Ashwatha Narayana et al. JOURNAL OF NEURO-ONCOLOGY
- Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain
- (2013) David J. Salvetti et al. JOURNAL OF NEUROSURGERY
- 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
- (2013) K. Tamura et al. JOURNAL OF NUCLEAR MEDICINE
- Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement
- (2013) Masayuki Takeda et al. Journal of Thoracic Oncology
- Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
- (2013) Denis Maillet et al. Journal of Thoracic Oncology
- Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
- (2013) T. Iuchi et al. LUNG CANCER
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
- (2013) Eamon M. Berge et al. SEMINARS IN ONCOLOGY
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- Vemurafenib and Radiosensitization
- (2013) Lise Boussemart et al. JAMA Dermatology
- Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)
- (2012) Y.- L. Wu et al. ANNALS OF ONCOLOGY
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
- (2012) Nils D. Arvold et al. BREAST CANCER RESEARCH AND TREATMENT
- Isolated central nervous system progression on Crizotinib
- (2012) Stephen G. Chun et al. CANCER BIOLOGY & THERAPY
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
- (2012) S.J. Park et al. LUNG CANCER
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
- (2012) Hsin-Lun Lee et al. Radiation Oncology
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
- (2011) Gianfranco A. Pesce et al. EUROPEAN JOURNAL OF CANCER
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
- (2011) Maria J. Sambade et al. RADIOTHERAPY AND ONCOLOGY
- Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma
- (2010) Agop Y. Bedikian et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
- (2010) R. Porta et al. EUROPEAN RESPIRATORY JOURNAL
- Gamma knife surgery for 1–10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria
- (2010) Toru Serizawa et al. JOURNAL OF NEURO-ONCOLOGY
- Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
- (2010) Josette Carnahan et al. MOLECULAR CANCER THERAPEUTICS
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
- (2010) A. F. Eichler et al. NEURO-ONCOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
- (2009) Brian Leyland-Jones JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
- (2009) Jeong-Eun Kim et al. LUNG CANCER
- Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer
- (2008) Hiroyuki Mano CANCER SCIENCE
- Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response
- (2008) C.-H. Gow et al. CLINICAL CANCER RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)
- (2008) J. W. Polli et al. DRUG METABOLISM AND DISPOSITION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started